13F Holdings
中文EN

EMMA Emmaus Life Sciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 822370 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.0%
TTM net income YoY-77.9%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR-18.2%
Net income 3-yr CAGR—

Margins

Gross margin93.6%
Operating margin29.3%
Net margin-38.8%
FCF margin—
EBITDA margin29.7%

Returns

ROE—
ROA-30.3%
ROIC (approx.)—
Asset turnover0.78x

Leverage & solvency

Liabilities / assets504.3%
Debt / equity—
Current ratio0.09x
Interest coverage0.57x

Cash quality & payout

Operating cash flow / net income-0.66x
Accruals ratio-50.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$12.45M$16.65M$29.60M$18.39M$20.61M
Cost of revenue$857,000$1.20M$1.34M$2.59M$3.31M
Gross profit$11.60M$15.45M$28.25M$15.80M$17.30M
R&D expense$313,000$657,000$1.19M$1.73M$4.11M
SG&A expense$8.18M$10.69M$14.89M$13.17M$13.44M
Operating income$231,000-$1.89M$3.54M-$6.59M-$6.13M
Interest expense$7.13M$5.49M$7.38M$5.01M$3.10M
Pretax income-$7.48M-$6.42M-$3.79M-$10.56M-$15.92M
Income tax$9,000$29,000-$59,000$60,000$25,000
Net income-$7.49M-$6.45M-$3.73M-$10.62M-$15.95M
EBITDA$270,000-$1.87M$3.57M-$6.53M-$6.07M
EPS (basic)-0.12-0.10-0.07-0.21-0.32
EPS (diluted)-0.12-0.10-0.07-0.21-0.32
Weighted avg. shares (diluted)64.04M63.23M53.11M49.44M49.25M
Balance sheet
Cash & equivalents$2.13M$1.39M$2.55M$2.02M$2.28M
Receivables$2.80M$2.62M$5.52M$375,000$1.04M
Inventory$1.55M$1.64M$1.71M$2.38M$4.39M
Current assets$7.75M$6.77M$11.51M$6.29M$9.09M
PP&E, net$113,000$46,000$59,000$75,000$147,000
Total assets$21.44M$23.60M$35.18M$48.23M$56.73M
Current liabilities$69.07M$63.55M$61.51M$54.32M$37.10M
Long-term debt$27.13M$28.96M$30.56M$30.42M$22.34M
Total debt$27.13M$28.96M$30.56M$30.42M$22.34M
Total liabilities$85.04M$80.08M$82.94M$82.32M$78.18M
Shareholders' equity-$63.61M-$56.48M-$47.76M-$34.09M-$21.45M
Net debt$25.00M$27.58M$28.02M$28.40M$20.06M
Shares outstanding70.19M63.87M61.85M49.58M49.31M
Cash flow statement
Operating cash flow-$11,000-$2.29M-$1.50M-$5.07M-$1.25M
Capital expenditure$1,000$12,000$17,000$26,000$73,000
Free cash flow-$12,000-$2.30M-$1.52M-$5.10M-$1.33M
Investing cash flow$2.17M$2.50M-$432,000-$2.39M-$6.38M
Financing cash flow-$1.43M-$1.35M$2.48M$7.23M$7.41M
Depreciation & amortization$39,000$22,000$32,000$53,000$59,000
Stock-based compensation$25,000$256,000$1.26M$16,000$553,000

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.